

January 24, 2023
H.E. António Guterres
Secretary-General
United Nations
New York, NY 10017
USA

Dear Secretary-General,


I am pleased to confirm that Pharma IT ApS supports the Ten Principles of the United Nations Global Compact on human rights, labour, environment and anti-corruption. With this communication, we express our commitment to making the UN Global Compact and its principles part of the strategy, culture and day-to-day operations of our company, and to engaging in collaborative projects which advance the broader development goals of the United Nations, particularly the Sustainable Development Goals. Pharma IT ApS will make a clear statement of this commitment to our stakeholders and the general public.

We recognize that a key requirement for participation in the UN Global Compact is the annual submission of a Communication on Progress (CoP) that describes our company's efforts to implement the Ten Principles. We support public accountability and transparency, and therefore commit to report on progress starting the calendar year after joining the UN Global Compact, and annually thereafter according to the UN Global Compact CoP policy.

This includes:

- A statement signed by the chief executive expressing continued support for the UN Global Compact and renewing our ongoing commitment to the initiative and its principles. This is separate from our initial letter of commitment to join the UN Global Compact.
- The completion of the online questionnaire of the Communication on Progress through which we will disclose our company's continuous efforts to integrate the Ten Principles into our business strategy, culture and daily operations, and contribute to United Nations goals, particularly the Sustainable Development Goals.

Sincerely yours,

DocuSigned by:
Jakob Juul Rasmussen
 Signer Name: Jakob Juul Rasmussen
Signing Reason: I approve this document
Signing Time: 24-Jan-2023 | 21:35:13 CET
529F0F90A17D4D44B452B7D812637D97

Mr. Jakob Juul Rasmussen
CEO/Co-Founder/Managing Director

Certifikat for færdiggørelse

Kuvert-id: D401E3577C1F4A2DA55ADAFF9CC626BB

Status: Gennemført

Emne: Complete with DocuSign: draft-CEO Letter of Commitment.pdf

Kildekuvert:

Dokumentsider: 1

Underskrifter: 1

Kuvertskaber:

Certifikatsider: 5

Initialer: 0

Jakob Juul Rasmussen

Autonavagation: Aktiveret

Ny Carlsberg Vej 80

Kuvertstempling: Deaktiveret

København V, Copenhagen 1760

Tidszone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris

jajr@pharmait.dk

IP-adresse: 87.49.147.147

Sporing af poster

Status: Original

Ihændeager: Jakob Juul Rasmussen

Sted: DocuSign

24-jan-2023 | 21:34

jajr@pharmait.dk

Hændelser for underskriver**Underskrift****Tidsstempel**

Jakob Juul Rasmussen

jajr@pharmait.dk

Managing Director

Pharma IT ApS

Sikkerhedsniveau: E-mail, Kontogodkendelse (påkrævet)

Jakob Juul Rasmussen

Sendt: 24-jan-2023 | 21:34

Vist: 24-jan-2023 | 21:35

Signeret: 24-jan-2023 | 21:35

Vælg underskrift: Forudvalgt stil

Underskrift-id:

529F0F90-A17D-4D44-B452-B7D812637D97

Brug af IP-adresse: 87.49.147.147

Med underskrivningsgodkendelse via

DocuSign-adgangskode

Med underskrivningsårsager (på hver fane):

I approve this document

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via DocuSign

Hændelser for personlig underskriver**Underskrift****Tidsstempel****Hændelser for redaktørlevering****Status****Tidsstempel****Hændelser for agentlevering****Status****Tidsstempel****Hændelser for midlertidig levering****Status****Tidsstempel****Hændelser for certificeret levering****Status****Tidsstempel****Hændelser for kopi (cc:)****Status****Tidsstempel**

Naomi Jade Kellogg

Kopieret

Sendt: 24-jan-2023 | 21:34

NaJK@pharmait.dk

Vist: 25-jan-2023 | 09:40

Sikkerhedsniveau: E-mail, Kontogodkendelse (påkrævet)

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 07-dec-2021 | 10:53

Id: d517a2a7-26f0-4101-bf44-f81b1a53ecb1

Vidnehændelser**Underskrift****Tidsstempel****Notarhændelser****Underskrift****Tidsstempel****Hændelser for kuvertoversigt****Status****Tidsstempler**

Hændelser for kuvertoversigt	Status	Tidsstempler
Kuvert sendt	Med hash/krypteret	24-jan-2023 21:34
Leveret certificeret	Sikkerhedskontrolleret	24-jan-2023 21:35
Signering fuldført	Sikkerhedskontrolleret	24-jan-2023 21:35
Gennemført	Sikkerhedskontrolleret	24-jan-2023 21:35

Betalingshændelser	Status	Tidsstempler
--------------------	--------	--------------

Oplysninger om elektroniske poster og underskrifter

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Pharma IT ApS (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Pharma IT ApS:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jajr@pharmait.dk

To advise Pharma IT ApS of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jajr@pharmait.dk and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Pharma IT ApS

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jajr@pharmait.dk and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Pharma IT ApS

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jajr@pharmait.dk and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Pharma IT ApS as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Pharma IT ApS during the course of your relationship with Pharma IT ApS.